106 related articles for article (PubMed ID: 23256719)
21. The therapeutic potential of CFTR modulators for COPD and other airway diseases.
Solomon GM; Fu L; Rowe SM; Collawn JF
Curr Opin Pharmacol; 2017 Jun; 34():132-139. PubMed ID: 29132121
[TBL] [Abstract][Full Text] [Related]
22. N-acetylcysteine in COPD: why, how, and when?
Sanguinetti CM
Multidiscip Respir Med; 2015; 11():8. PubMed ID: 26855777
[TBL] [Abstract][Full Text] [Related]
23. Comparison between cigarette smoke-induced emphysema and cigarette smoke extract-induced emphysema.
He ZH; Chen P; Chen Y; He SD; Ye JR; Zhang HL; Cao J
Tob Induc Dis; 2015; 13(1):6. PubMed ID: 25814921
[TBL] [Abstract][Full Text] [Related]
24. Oxidative stress and free radicals in COPD--implications and relevance for treatment.
Domej W; Oettl K; Renner W
Int J Chron Obstruct Pulmon Dis; 2014; 9():1207-24. PubMed ID: 25378921
[TBL] [Abstract][Full Text] [Related]
25. N-Acetylcysteine increases corneal endothelial cell survival in a mouse model of Fuchs endothelial corneal dystrophy.
Kim EC; Meng H; Jun AS
Exp Eye Res; 2014 Oct; 127():20-5. PubMed ID: 24952277
[TBL] [Abstract][Full Text] [Related]
26. Reducing agents decrease the oxidative burst and improve clinical outcomes in COPD patients: a randomised controlled trial on the effects of sulphurous thermal water inhalation.
Contoli M; Gnesini G; Forini G; Marku B; Pauletti A; Padovani A; Casolari P; Taurino L; Ferraro A; Chicca M; Ciaccia A; Papi A; Pinamonti S
ScientificWorldJournal; 2013; 2013():927835. PubMed ID: 24453924
[TBL] [Abstract][Full Text] [Related]
27. Antioxidant therapeutic advances in COPD.
Rahman I
Ther Adv Respir Dis; 2008 Dec; 2(6):351-74. PubMed ID: 19124382
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological and dietary antioxidant therapies for chronic obstructive pulmonary disease.
Biswas S; Hwang JW; Kirkham PA; Rahman I
Curr Med Chem; 2013; 20(12):1496-530. PubMed ID: 22963552
[TBL] [Abstract][Full Text] [Related]
29. Oxidation pathway and exacerbations in COPD: the role of NAC.
Matera MG; Calzetta L; Cazzola M
Expert Rev Respir Med; 2016; 10(1):89-97. PubMed ID: 26567752
[TBL] [Abstract][Full Text] [Related]
30. Antioxidant pharmacological therapies for COPD.
Rahman I; MacNee W
Curr Opin Pharmacol; 2012 Jun; 12(3):256-65. PubMed ID: 22349417
[TBL] [Abstract][Full Text] [Related]
31. Antioxidants and mucolytics in COPD management: when (if ever) and in whom?
Hillas G; Nikolakopoulou S; Hussain S; Vassilakopoulos T
Curr Drug Targets; 2013 Feb; 14(2):225-34. PubMed ID: 23256719
[TBL] [Abstract][Full Text] [Related]
32. Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD.
Cazzola M; Page CP; Wedzicha JA; Celli BR; Anzueto A; Matera MG
Respir Res; 2023 Jul; 24(1):194. PubMed ID: 37517999
[TBL] [Abstract][Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
